📰 Morphosys Group News
Morphosys Group News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Morphosys Group. Real-time updates on events, politics, business and more.
December 12, 2021
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous/Conference12.12.2021 / 15:00 The issuer is solely responsible for the content of this announcement.MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis Data presented during poster...
December 12, 2021
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American
November 30, 2021
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous29.11.2021 / 22:02 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, November 29, 2021MorphoSys AG: Corporate Calendar 2022 Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follow...
November 29, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022Dear Madam/Sir,Please note MorphoSys' financial reporting dates 2022 as follows:Publication of Interim Statement / ReportConference
November 4, 2021
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathyPLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 4
November 2, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to €
October 20, 2021
Press release content from Accesswire. The AP news staff was not involved in its creation.
October 11, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food
October 11, 2021
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous11.10.2021 / 08:47 The issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, October 11, 2021MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease Morph...
August 17, 2021
DGAP-News: MorphoSys AG / Key word(s): Miscellaneous17.08.2021 / 08:07 The issuer is solely responsible for the content of this announcement.Media ReleaseMorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater ChinaPlanegg/Munich, Germany - August 17,...